Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Jul. 11, 2024--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2024 financial results before the market opens on Friday, August 2, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.
科技公司富朗特遗传学(Fulgent Genetics, Inc.)(Nasdaq:FLGT)宣布,将于2024年8月2日星期五美东时间早上8:30(太平洋时间早上5:30)公布2024年第二季度财务业绩,并在当天为投资社区主办电话会议,以讨论业绩情况并回答问题。该公司以业务服务和治疗发展为基础。
The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, . An audio replay will be available at the same location.
投资者可通过公司网站的投资者关系部分收听电话会议的现场音频网络广播。音频重播将在同一位置提供。
About Fulgent
关于Fulgent
Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent's laboratory services business, which was formerly referred to as the clinical diagnostic business, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Fulgent's therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.
Fulgent是一家以技术为基础的公司,拥有业务已经很成熟的实验室服务和治疗开发业务。 Fulgent的实验室服务业务(曾被称为临床诊断业务)包括技术实验室服务和获得执照医生对实验室结果的专业解释。 Fulgent的治疗开发业务专注于开发新型纳米包裹和靶向治疗平台来治疗广泛的癌症药物,以提高新的和现有的抗癌药物的治疗窗口和药代动力学特性。 该公司旨在从基因组诊断业务转变为一家完全集成的精准医疗公司。
View source version on businesswire.com:
请查看商业线(businesswire.com)的源版本。
Investor Relations Contact:
The Blueshirt Group
Melanie Solomon, melanie@blueshirtgroup.com
投资者关系联系人:
The Blueshirt Group
Melanie Solomon,melanie@blueshirtgroup.com
Source: Fulgent Genetics, Inc.
消息来源:富朗特遗传学公司